Work it at three levels: the contribution of one treatment, the gross margin of the practice, and EBITDA after rent, the medical director and the owner's salary.
A med spa's profit margin is best read at three levels: the contribution of one treatment after product and card fees, the gross margin after staff pay, and EBITDA after site costs and overhead. In the fictional case of the book, a neurotoxin treatment contributes $289, a filler syringe $454, and the practice's EBITDA is 21.0% of $2,455,483 of revenue in FY2026.
Worked in full in The Med Spa Owner by Julian R. Sterling.Get the DRM-free PDF, $19.99 →or the paperback
Free: the Med Spa Treatment Margin and Break-Even Calculator, an Excel workbook that returns the contribution per treatment and per room hour, the treatments a month to break even and the cost of a member discount.
A med spa's profit margin is not one number. The contribution per treatment is the price of one appointment less the product it uses and the card fee on it. The gross margin is revenue less all direct costs, which in this case include clinical and front desk pay. EBITDA is what is left after rent, the medical director's fee, software, insurance, marketing and the owner's own salary. An owner who knows only the last one cannot tell which treatment, room or hire moved it.
The figures below come from Corvelline, the fictional practice of the book: a first site with three treatment rooms and, from 1 April 2026, a second site with two. No industry average is quoted here, because none was verified from a primary source; the method is what carries over to your own numbers.
The case prices neurotoxin by the unit. Its average treatment uses 37.4 units of a botulinum toxin type A product (a pricing average set by the case, never a dosing guide: units are decided by the treating clinician under the medical director's standing orders). At the FY2026 price of $14.00 a unit and a product cost of $5.90 a unit, with card fees of 2.75% on every receipt:
Price = 37.4 × $14.00 = $524 (rounded)
Product = 37.4 × $5.90 = $221; card fee = 2.75% × $524 = $14
Contribution = $524 − $221 − $14 = $289, or $578 for each hour of room time (30 minutes a treatment)
The same arithmetic on the other three kinds of treatment gives the table that drives the schedule.
| Treatment | Price | Contribution | Per room hour |
|---|---|---|---|
| Neurotoxin (37.4 units) | $524 | $289 | $578 |
| Filler, one syringe | $775 | $454 | $605 |
| Laser or light session | $295 | $262.10 | $349 |
| Aesthetician service | $175 | $155 | $155 |
The book goes further: seven Excel workbooks (treatment margin, membership, injector pay, laser buy, lease or rent, break-even, second location payback, offer and value), each with an exercise and its answer. See The Med Spa Owner · PDF, $19.99
The contribution per hour of room time is the measure that ranks treatments in a med spa, because rooms and clinicians' hours are the scarce resource. In the case a filler syringe earns $605 an hour over 45 minutes and a neurotoxin treatment $578 over 30 minutes, while a laser session earns $349 and an aesthetician service $155. The filler syringe earned the most per hour of room time and the aesthetician service the least. That does not mean dropping facials: they fill rooms that would otherwise sit empty and bring members back each month. It means a filler appointment should never wait behind a free facial slot.
Members of the case's plan pay 90% of the unit and syringe price. On the same 37.4-unit treatment the member pays $471 instead of $524. The product still costs $221, the card fee falls only to $13, and the contribution drops from $289 to $237.
The trap: a 10% price discount cut the treatment's contribution by 18.0%, because the product cost does not move. A discount is paid for by the plan fee. At the first site in FY2026 membership fees of $346,528, less the discounts given, the supplies of the included services and the card fees, left $262,521 over 2,912 member-months, or $90.15 a member-month.
The gross margin of a med spa is revenue less product, clinical and site staff pay, card fees and chargebacks. Corvelline reads its two entities together (the management fee paid by the professional corporation to the management company nets to zero), which gives this income statement.
| Line | FY2025 | FY2026 |
|---|---|---|
| Revenue | $1,753,366 | $2,455,483 |
| Direct costs | $955,043 | $1,320,261 |
| Gross margin | $798,323 (45.5%) | $1,135,222 (46.2%) |
| Site operating expenses | $313,800 | $473,340 |
| Company overhead | $140,544 | $147,180 |
| EBITDA | $343,979 (19.6%) | $514,702 (21.0%) |
At the first site in FY2026, product was 30.6% of revenue and staff pay with its burden 18.6%, and the site's contribution after rent, the medical director, marketing and the other site costs was $645,183, 32.1% of its revenue. The second site, open six months, contributed $16,699. EBITDA was higher in FY2026 in dollars and as a share of revenue, and it still includes the owner's salary of $120,000 as a cost: a buyer reads it differently, as the article on what a med spa is worth shows.
In the case, product is the largest direct cost, which makes a cheaper source tempting. The FDA's alert of April 2024 on counterfeit botulinum toxin, found in multiple states and administered for cosmetic purposes, says the products appear to have come from unlicensed sources and that federal law requires providers who administer prescription drugs to buy them only from authorized sources. Neurotoxins are prescription drugs under 21 U.S.C. 353(b) as in force in November 2026. The case buys every product from the manufacturer or its authorized distributor and keeps invoices and lot records; margin is managed through price, the room hour and the discount, never through the supply chain.
Rules checked on 17 November 2026, federal only, and not legal, tax, accounting or medical advice. Corvelline, its bank, lessor and landlord are fictional: every case figure is a teaching assumption, not a market norm, and the units are not a dosing guide. State law is for counsel in the practice's state.
No benchmark is given here because none was verified from a primary source. In the fictional case of the book, EBITDA was 19.6% of revenue in FY2025 and 21.0% in FY2026, after paying the owner a salary. Compute your own at three levels: per treatment, gross margin and EBITDA.
Measure it per hour of room time, not per ticket. In the case at FY2026 prices a filler syringe earned $605 an hour before staff pay, a neurotoxin treatment $578, a laser session $349 and an aesthetician service $155.
Both. The 10% member discount cut a neurotoxin treatment's contribution from $289 to $237, but at the first site the plan still added $90.15 a member-month net of discounts, included-service supplies and card fees.
In the case, yes: the owner's salary and its burden sit in company overhead, above EBITDA. A buyer adds it back and then deducts what a replacement injector would cost.
This article is one chapter's worth of arithmetic from The Med Spa Owner, which follows one fictional two-site practice for 24 months: the professional corporation and the management company, the medical director, pricing by the unit and the syringe, injector pay, lasers, memberships, break-even, a second location and a letter of intent.
DRM-free PDF, $19.99 · Paperback, $32.99, shipped worldwide · Free calculator